Initial public offerings by drug developers continue to find a market in the US even though biotechnology stocks are not performing well compared with broader stock indices. Momentum is building, however, as investors continue to chase gene therapy and targeted oncology companies that may offer opportunities for big money pharma buyouts, according to a 1 July report from Jefferies.
Analysts Andrew Tsai, Kelechi Chikere and Arshad Haider tracked 29 biopharma IPOs in the US during the first half of...






